4D Molecular Therapeutics, Inc. (FDMT)

23.53 -0.72 (-2.97%) At close: 04:00PM EDT

4D Molecular Therapeutics, Inc.

5858 Horton Street
Suite 455
Emeryville, CA 94608
United States
510 505 2680
https://www.4dmoleculartherapeutics.com

Sector(s): Healthcare
Industry: Biotechnology
Full-time employees: 147

Key executives

Name	Title	Pay	Exercised	Year born
Dr. John F. Milligan Ph.D.	Executive Chairman	150k	N/A	1961
Dr. David H. Kirn M.D.	Co-Founder, CEO & Director	1.01M	N/A	1963
Dr. Fariborz Kamal Ph.D.	President & COO	786.2k	N/A	1963
Dr. Noriyuki Kasahara M.D., Ph.D.	Chief Scientific Officer	201.29k	N/A	1963
Dr. Robert Y. Kim M.B.A., M.D.	Chief Medical Officer	704.84k	N/A	1961
Ms. Theresa Janke	Co-Founder & Chief of Staff	652.32k	N/A	1975
Mr. Uneek Mehra	Chief Financial & Business Officer	N/A	N/A	1972
Dr. Scott P. Bizily J.D., Ph.D.	Chief Legal Officer & Corporate Secretary	N/A	N/A	1973
Dr. An Song Ph.D.	Chief Development Officer	N/A	N/A	N/A
Dr. Alan H. Cohen FAAAAI, FAAP, FACAAI, FCCP, M.D.	Senior VP & Therapeutic Area Head of Pulmonology	N/A	N/A	1961

Amounts are as of 31 December 2023, and compensation values are for the last fiscal year ending on that date. Pay includes salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

4D Molecular Therapeutics, Inc., a clinical-stage biotherapeutics company, develops genetic medicines using its therapeutic vector evolution platform in the Netherland and the United States. The company develops a portfolio of genetic medicine product candidates focuses in three therapeutic areas for ophthalmology, cardiology, and pulmonology. Its product pipeline includes 4D-150, which is in phase 1/2 clinical trial for the treatment of wet age-related macular degeneration; and is in phase 1/2 clinical trial for the treatment of diabetic macular edema. The company develops 4D-125, which is in phase 1/2 clinical trial for the treatment of x-linked retinitis pigmentosa; 4D-110, which is in phase 1/2 clinical trial for the treatment of choroideremia; 4D-710, which is in phase 1/2 clinical trial for the treatment cystic fibrosis lung disease; and 4D-310 to treat fabry disease cardiomyopathy and is in phase 1/2 clinical trial. In addition, its product candidates comprises 4D-175, which is in pre-clinical development for the treatment for geographic trophy; and 4D-725 to treat alpha-1 antitrypsin deficiency lung disease and is in pre-clinical development. The company has collaboration and licensing agreements with Arbor Biotechnologies, Inc.; Astellas Gene Therapies, Inc; uniQure biopharma B.V.; and Cystic Fibrosis Foundation. 4D Molecular Therapeutics, Inc. was founded in 2013 and is headquartered in Emeryville, California.

Corporate governance

4D Molecular Therapeutics, Inc.’s ISS governance QualityScore as of 1 April 2024 is 7. The pillar scores are Audit: 2; Board: 6; Shareholder rights: 8; Compensation: 9.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while 10 indicates higher governance risk.